Hot Investor Mandate: Subsidiary of Large China CRO Seeking Investment Opportunities in Cell/Gene Therapy, Cell Engineering, and Life Sciences Tools

18 Oct

An emerging company is focused on the development of the best-in-class immunotherapy technology for cancer cure. Teamed up with outstanding immunologists and molecular biologists, the firm has generated a strong pipeline of Chimeric Antigen Receptor (CAR) product candidates to treat a wide variety of liquid and solid tumors. Legend Biotech is a subsidiary company of a large Chinese CRO. The firm is actively seeking investment, partnering and licensing opportunities to expand the pipeline of therapeutics and offerings. Typical allocations are $1-10 M.

The firm’s sectors of focus are cell and gene therapies, cell engineering, processing and manufacturing technologies and tools.

The firm may seek a board seat depending upon size of investment. They are open to working with all stages of management teams. The firm can either lead or co-invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: